Indeed, we noticed upregulation of the activation markers CD40 and CD86 on TDLN cDC1s after treatment with CD8α ALN-1, which is in line with earlier reports.15 37 As can be expected from the critical role of cDC1s in the cancer-immunity cycle,1 basal proliferation of OT-I CD8+ T cells in response to TAA was strongly reduced in full-body Batf3-/- mice, which lack a functional cDC1 compartment. Here, CD86 is linked to cancer.